Immunocore Holdings (IMCR) Non Operating Income (2021 - 2023)

Immunocore Holdings (IMCR) has reported Non Operating Income for 3 consecutive years, with $2.3 million the latest figure, recorded in Q2 2023.

• Quarterly Non Operating Income rose 238.73% year-over-year to $2.3 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$1.6 million (changed N/A YoY) and the FY2022 annual result came in at -$5.3 million, up 32.91% from the prior year.
• Non Operating Income grew to $2.3 million in Q2 2023 per IMCR's latest filing, from -$877350.4 in the prior quarter.
• Over the last five years, Non Operating Income for IMCR reached as high as $2.3 million in Q2 2023 and fell as low as -$1.8 million in Q4 2021.
• A 3-year average of -$874535.8 and a median of -$1.5 million in 2022 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income advanced 22.41% — and 2023, when it jumped 238.73%.
• Year by year, Non Operating Income stood at -$1.8 million in 2021, then jumped by 51.54% to -$877350.4 in 2022, then jumped by 363.44% to $2.3 million in 2023.
• According to Business Quant data, Non Operating Income over the past three periods registered $2.3 million, -$877350.4, and -$1.4 million for Q2 2023, Q4 2022, and Q3 2022 respectively.